We were very pleased to welcome four really interesting companies to our November London South East webinar which took place on Tuesday evening 8 November 2022.
We had two Life Sciences companies and two mining business for you, and here are their video presentations.
Suzanne Dilly, CEO at ValiRx - 01:39 and Q&A at 20:54
ValiRx (AIM:VAL) is a life science company focused on early stage cancer therapeutics and women’s health. It has recently established a new 60% owned subsidiary called Cytolytix which has signed an IP Licence Agreement with King’s College London to progress a breast cancer treatment called CLX001 through preclinical trials.
Jeremy Skillington, CEO Poolbeg Pharma - 32:15 and Q&A at 52:52
Poolbeg Pharma (AIM:POLB) is a clinical stage infectious disease pharmaceutical company, with a unique capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company aspires to become a "one-stop shop" for pharma and biotech seeking mid-stage products to license or acquire and is targeting the growing infectious disease market.
William M Sheriff, Executive Chair, enCore Energy - 1:03:24 and Q&A at 1:22:10
enCore Energy (TSXV: EU OTC:ENCOD) is the most diversified ‘in-situ recovery’ uranium development company in the United States. Today it has a potential estimated 90 million pounds of U3O8 (yellowcake) in the measured and indicated categories and 9 million pounds of U3O8 in the inferred category. It has short, medium and long term opportunities and intends to produce uranium from its licensed and past-producing South Texas Rosita Processing Plant by 2023.
Werner Klingenberg, CEO, Goldplat - 1:35:20 and Q&A at 1:55:25
Goldplat (AIM:GDP) the South Africa-based gold producer with international gold recovery operations located in South Africa and Ghana has sold the Kilimapesa gold mine in Kenya and refocused the profitable core business. Goldplat is on a solid growth trajectory, and with a market cap of 17M pounds the shares are trading at an all time high. GDP is developing a gold tailings recovery revenue stream in South Africa.
GoldPlat (GDP)
Poolbeg Pharma (POLB)
ValiRx (VAL)